Trials / Recruiting
RecruitingNCT05890729
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 94 (estimated)
- Sponsor
- Xentria, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XTMAB-16 or Placebo | Infusion |
Timeline
- Start date
- 2023-11-10
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2023-06-06
- Last updated
- 2025-11-25
Locations
34 sites across 6 countries: United States, Czechia, Denmark, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05890729. Inclusion in this directory is not an endorsement.